Date: Wed 28/10/2020 - Fri 28/10/2022
Provider: Specsavers ANZ
Optometrist Credits: 0.50 General Credits + 0.50 Clinical Diagnostic Credits
Event Type(s): Online
Optical coherence tomography (OCT) imaging allows a more granular information to be obtained regarding the severity of age-related macular degeneration (AMD) as many novel risk factors having been recently identified on OCT. With this imaging information, we are better able to counsel our patients with more accurate and individualized progression scenarios. OCT also allows identification of anatomical features that increase our ability to monitor disease progression in smaller stages then just determining if late exists. Treatment protocols for neovascular AMD (nAMD) depend largely on the optical coherence tomography (OCT) appearance to determine disease activity, which allows individualize treatments. In geographic atrophy (GA), it is now possible to identify the first signs of atrophy on OCT, long before it is seen as GA, which is crucial as we strive to bring interventions earlier in the course of the disease course.
1. Be able to correctly classify AMD based on colour fundus photos (Beckman classification scheme)
2. Be able to identify AMD biomarkers on optical coherence tomography (OCT)
3. Demonstrate a clear understanding of how these imaging biomarkers should guide patient management